Bye, bye blockbusters, hello niche busters

Collier, Roger
August 2011
CMAJ: Canadian Medical Association Journal;8/9/2011, Vol. 183 Issue 11, pE697
Academic Journal
The article presents suggestions on how pharmaceutical companies can re-drive their profits, when patents on blockbuster drugs expire across the world. It defines the concept of blockbuster philosophy, which has dominated the pharmaceutical industry and proposes that drugs should be developed for as many people as possible so as to achieve sales of at least one billion dollars. It highlights a parallel drug diagnostic model, which can increase the efficacy of pharmaceutical companies.


Related Articles

  • ACC Pearls.  // Formulary;May2001, Vol. 36 Issue 5, p367 

    Reports developments related to the drug industry in the United States as of May 2001. Effects of clopidogrel on patients with acute coronary syndrome; Effectiveness of rosuvastatin in reducing low-density lipoprotein cholesterol; Comparison of hospitalization costs between invasive and...

  • Neurochem: excitement builds as Alzhemed phase III trial is completed.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p19 

    The article reports on the completion of a phase III clinical trial by Neurochem Inc. for its Alzheimer's disease (AD) treatment Alzhemed. The phase III clinical trial has investigated the safety, efficacy and disease-modifying potential of Alzhemed for the treatment of mild-to-moderate AD...

  • Omnitarg (Breast Cancer) - Analysis and Forecasts to 2020.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article provides information on the report, Analysis and Forecast to 2020 by the company GlobalData. It states that the pharmaceutical report provide estimates for Omnitarg sales for the U.S and EU5. It reflects the report includes the clinical assessment of the drug, drug sales and sales...

  • Is pharmacogenomics a reality? Challenges and oppurtunities for India. Banerjee, Moinak // Indian Journal of Human Genetics;May-Aug2011 Supplement, Vol. 17, pS1 

    The author reflects on the challenges and opportunities that pharmacogenomics will brought to India. He states that even though India has the 20% of the world population, their pharmaceutical market is only two percent of the global market. The author says that most of the pharmaceutical...

  • Vantage Point. McDonald, Susan Schwartz // Medical Marketing & Media;Feb2012, Vol. 47 Issue 2, p25 

    The article reports on a survey conducted to 156 leaders in the U.S. and Europe which reveals that 68% of respondents believed that the commercial pharmaceutical model is broken.

  • News Capsules.  // Formulary;May2001, Vol. 36 Issue 5, p325 

    Reports developments related to the drug industry in the United States as of May 2001. Effects of endothelins receptor antagonist on heart failure; Comparison between the effectiveness of rivastigmine and donepezil in treating Alzheimer's disease; Level of formulary acceptance of the drugs...

  • Metabonomics Treats Attrition in Early Drug Discovery. Kube, D.M. // Drug Discovery & Development;Mar2003, Vol. 6 Issue 3, p45 

    Discusses the applications of metabonomics in the screening for drug safety and efficacy. Definition of metabonomics; Profiling of metabolites to evaluate the physiological status of an organism as a whole; Link of metabonomics to genomics, transcriptomics and proteomics; Advantages of...

  • Drug Watch.  // Formulary;Dec2005, Vol. 40 Issue 12, p460 

    The article reports on news and developments in pharmaceuticals. A chart is provided on selected dermatologic disorders. Selected literature on calcipotriene/betamethasone, ceftobiprole , dalnavancin and oritavancin is presented. A drug development setback on tazarotene for the treatment of...

  • Accelerating drug discovery. Kraljevic, Sandra; Stambrook, Peter J.; Pavelic, Kresimir // EMBO Reports;Sep2004, Vol. 5 Issue 9, p837 

    Provides some insights into the drug development process and its implications for the pharmaceutical industry. Investments in drug development in the U.S. and Europe; Issues on drug safety, quality and efficacy; Industrial costs and market trends.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics